Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zarnestra in High-Risk MDS
NCT00050154Phase 2Completed
- Sponsor
- Johnson & Johnson
- Start
- Jul 2002
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of tipifarnib in myelodysplastic syndrome (MDS), sponsored by Johnson & Johnson. Started Jul 2002; status: completed.
02
Drugs
tipifarnib
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00050154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00050154.